Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Antibodies: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Blood-Brain Barrier | targets | process | 0.85 |
| Myelitis Pathophysiology | involved_in | process | 0.80 |
| Neurodegeneration | treats | disease | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu | 0.773 | neurodegeneration | Blood-brain barrier transport mechanisms |
| APOE4-Targeted Microglial Reprogramming via Anti-APOE4 Antib | 0.670 | neurodegeneration | Test Hypothesis Fixtures |
| AQP4 Autoantibodies in NMOSD Cause Bystander Oligodendrocyte | 0.560 | neurodegeneration | What are the specific molecular mechanis |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Development and validation of triple knock-in humanized mice | validation | COVID-19/SARS-CoV-2 infection | 0.900 | 0.00 | Triple knock-in mice expressin | proposed | N/A |
| Pharmacokinetic evaluation of humanized mAbs in IgG1-Fc humanized mice | validation | 0.800 | 0.00 | IgG1-Fc humanized hFCGRT trans | proposed | N/A | |
| s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - Compare uptake with/without magnetic particles using tight junc | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $120,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxic | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease. [PMID:40425446] | Sehlin D, Hultqvist G, Michno W, Aguilar | J Prev Alzheimers Dis | 2025 | 1 |
| A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy [PMID:40020261] | Ana-Sosa-Batiz F, Verma SK, Shafee N, Mi | EBioMedicine | 2025 | 1 |
| The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene [PMID:33717213] | Dalakas MC, Spaeth PJ | Ther Adv Neurol Disord | 2021 | 1 |
| Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human [PMID:33025844] | Low BE, Christianson GJ, Lowell E, Qin W | MAbs | 2020 | 1 |
| Impact of Neonatal Fc Receptor on Transferrin Receptor Antibody Fusion Protein P [PMID:41755010] | ["Oyegbesan A", "Jagadeesan N", "Chandra | Pharmaceutics | 2026 | 0 |
| ROS-responsive nanogels for brain targeted delivery of icariin in the treatment [PMID:41197818] | ["Li X", "Huang J", "Zhou Y", "Chen X", | International journal of pharm | 2026 | 0 |
| A humanized transferrin receptor 1-transferrin model supports functional iron ho [PMID:41338456] | Yesiltepe M, Metkar S, Yin T, Chakrabort | The Journal of biological chem | 2026 | 0 |
| Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next- [PMID:41199078] | ["Ranjitha V", "Kumar A", "Kaalappa P"] | Pharmaceutical research | 2025 | 0 |
| A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and acti [PMID:39676023] | ["Sehlin D", "Roshanbin S", "Zachrisson | Neurotherapeutics : the journa | 2025 | 0 |
| Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic a [PMID:40715281] | Lee S, Kyung M, Park M, Park S, Lee J, K | Scientific reports | 2025 | 0 |
| Development of a Novel Engineered Antibody Format for PSMA-Targeted Radionuclide [PMID:40403225] | ["Fletcher N", "Houston Z", "Chandler P" | Molecular pharmaceutics | 2025 | 0 |
| Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood-Brain B [PMID:41031862] | ["Guo K", "Cao D", "Marchese-Thomas L", | Bioconjugate chemistry | 2025 | 0 |
| Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope [PMID:41110474] | ["David M", "Cohen R", "Beuzelin D", "Fe | Journal of controlled release | 2025 | 0 |
| Redefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therap [PMID:40807149] | ["Ciarmatori N", "Quaranta Leoni F", "Qu | Journal of clinical medicine | 2025 | 0 |
| Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746] | ["Sanadgol N", "Abedi M", "Hashemzaei M" | Journal of nanobiotechnology | 2025 | 0 |
| A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediate [PMID:39715817] | ["Petersen I", "Morrison J", "Petrovic A | Scientific reports | 2024 | 0 |
| RNA therapies for CNS diseases. [PMID:38494152] | ["Di Francesco V", "Chua A", "Huang D", | Advanced drug delivery reviews | 2024 | 0 |
| An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission. [PMID:37932271] | ["Li W", "Wang T", "Rajendrakumar A", "A | Nature communications | 2023 | 0 |
| Strategies to identify, engineer, and validate antibodies targeting blood-brain [PMID:38007619] | ["Choi E", "Shusta E"] | Expert opinion on drug deliver | 2023 | 0 |
| Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Compre [PMID:36077002] | ["Ramdani Y", "Lamamy J", "Watier H", "G | International journal of molec | 2022 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning Antibodies in their description or question text
No additional research found